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Figure 1 MboII restriction site on human MTHFR (GenBank
accession U09806). MboII recognizes GAAGA (upper nucleotide se-
quence). MTHFR 1298C (lower sequence) abolishes the MboII site.
Sequence data were obtained from GenBank (accession number
U09806). The lower sequence is identical to the GenBank sequence.
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The 1298(ArC) Mutation of
Methylenetetrahydrofolate Reductase Should Be
Designated to the 1289 Position of the Gene
To the Editor:
van der Put et al. (1998) recently reported that a second
commonmutation within the gene coding for the enzyme
methylenetetrahydrofolate reductase (MTHFR; E.C.
1.5.1.20) results in significantly reduced catalytic activ-
ity. This mutation is important because MTHFR plays
a significant role in the metabolism of folate and, ulti-
mately, of homocysteine, which is implicated as a risk
factor for neural-tube defects (Copp et al. 1990). van
der Put et al. (1998) designated this mutation—MTHFR
1298(ArC)—as changing a glutamate into an alanine
residue. A review of the human MTHFR mRNA se-
quence (GenBank accession number U09806) shows that
this mutation is not present in the human sequence at
position 1298 but may, in fact, be mutation 1289(ArC).
There are two reasons why this may be so. First, the
nucleotide at 1298 is a T (fig. 1). Second, the authors
report that this mutation, 1298C, destroys an MboII
restriction site. The recognition site for MboII is GAA-
GANNNNNNN/N/. There is no MboII restriction site
at 1298; however, there is one at 1289 in the human
MTHFR sequence (fig. 1). The enzymeMboII is expected
to cut between nucleotides 1297 and 1298, whereas the
mutation they describe is likely to be at position 1289.
Although this does not affect the results of their study,
it is important to accurately designate mutations to the
proper nucleotide position, thereby avoiding errors in
subsequent research concerning this important gene.
JAMES G. DONNELLY
Department of Pathology and Laboratory Medicine,
Ottawa Hospital, and Departments of Biochemistry,
Immunology and Microbiology, and Pathology and
Laboratory Medicine, Faculty of Medicine, University
of Ottawa, Ottawa, Canada
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Reply to Donnelly
To the Editor:
Donnelly comments, in his letter, on the confusing num-
bering used for the nomenclature of the second single-
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nucleotide polymorphism (SNP) discovered in the meth-
ylenetetrahydrofolate reductase (MTHFR) gene (Van der
Put et al. 1998). We agree that the numbering that was
used may be confusing for two reasons.
First, we designated this SNP as the “1298(ArC)
mutation,” by use of the same numbering method
used to indicate the 677(CrT) substitution, the first
SNP discovered in the MTHFR gene (Frosst et al.
1995). Although this SNP is designated to be at po-
sition 677, the actual location of this SNP may be at
position 665 of the coding region, if numbering is
started at the first ATG site of the reported coding
sequence (Goyette et al. 1994). Thus, discrepancies in
numbering started before the discovery of the second
SNP. We therefore had two options for determining
the nomenclature of the second SNP in the MTHFR
gene: either to start numbering at the ATG or to use
the method of numbering that is in concordance with
that used for the first SNP. In our opinion, this last
option would be more reasonable, because of the
widely accepted nomenclature of the 677(CrT) sub-
stitution. Therefore, we designated the second SNP as
the “1298(ArC) mutation.”
Second, the sequence reported by Goyette et al. (1994)
unfortunately contained a C at the 1298 sequence, in-
stead of at the much more common 1298A sequence, of
the MTHFR gene. We have no doubt that the mutation
is an ArC, rather than a CrA, transition, which is
clearly reflected by the prevalence of the 1298 SNP and
its effect on MTHFR activity (van der Put et al. 1998).
Additionally, we would like to describe an improved
method of PCR/RFLP screening for the 1298 SNP. By
use of two PCR primers—forward primer ATGTGG-
GGGGAGGAGCTGAC and the intronic reverse primer
GTCTCCCAACTTACCCTTCTCCC—a 241-bp frag-
ment will be obtained. If the wild-type genotype
(1298AA) is present, then the MboII RFLP results in
two fragments—one that is 204 bp and one that is 37
bp. For the homozygous mutated MTHFR genotype
(1298CC), only the 241-bp fragment is obtained, and,
for the heterozygous genotype, all three fragments are
obtained. These RFLP fragments can be easily differ-
entiated by means of agarose-gel electrophoresis.
We examined the possible interference of the
1317(TrC) transition with the proper screening of the
1298 SNP. 1317(TrC) is a silent mutation (Weisberg
et al. 1998) that, like the 1298 SNP, results in the
formation of an MboII recognition site and that could
thus disturb genotyping of 1298. We performed re-
striction-enzyme analysis with MboII and BpuAI—
the latter restriction enzyme recognizes only the
1317(TrC) substitution—on the PCR-obtained 241-
bp fragment and looked for possible misinterpretation
of the 1298 genotype. The 1317CC genotype was not
observed among 450 Dutch individuals, and we ob-
served only 3 heterozygous individuals, which re-
sulted in the 1317C allele having a frequency of .003
among the Dutch population. The 1317 SNP did not
interfere with the proper genotyping of 1298; in all
three cases, the 1317C allele was present on a 1298A
allele, which already results in a MboII recognition
site. Possibly, the 1317C substitution arose at the
1298A allele and, thus, will not disturb genotyping
of 1298.
NATHALIE M. J. VAN DER PUT
AND HENK J. BLOM
Department of Pediatrics
University Hospital Nijmegen
Nijmegen, the Netherlands
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Special Oversight Groups to Add Protections for
Population-Based Repository Samples
To the Editor:
The National Institute of General Medical Sciences
(NIGMS) supports the Human Genetic Cell Repository
through a contract to the Coriell Institute for Medical
Research in Camden, NJ. The repository supplies cell
lines and DNA samples to investigators worldwide. Al-
